Endo International PLC (NASDAQ:ENDP) saw its shares shed 3% in pre-market trading after the company confirmed that its subsidiary, Endo Pharmaceuticals Inc., has received a grand jury subpoena from the US Attorney's Office for the Southern District of Florida.
In a statement, the company said the subpoena is seeking information relating to products containing the opioid oxymorphone.
It said it also is seeking documents including those produced in past or pending lawsuits, as well as those relating to safety and efficacy, overdoses, abuse/misuse and overprescribing, among other issues.
The group said it intends to cooperate with the subpoena and any related investigation.
In pre-market trading in New York, Endo International shares were down 3% at US$7.83.